Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas

John H. Edmonson, Jan C. Buckner, Harry J. Long, Charles L. Loprinzi, Daniel J. Schaid

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Between April 1987 and July 1988, 44 adults with histologically proven, objectively assessable advanced nonosseous sarcomas were treated with 2.5 g of ifosfamide/m2,100 mg of etoposide/m2, and 2.5 g of mesna/m2 (500 mg/m2 × 5) daily for 3 consecutive days every 4 weeks. This regimen was generally well tolerated as outpatient treatment. Because of the potential CNS effects of ifosfamide, we recommend that elderly patients, persons receiving high doses of opiates, and patients susceptible to the syndrome of vertigo, perspiration, and hypotension (without tachycardia) be hospitalized for treatment At initial treatment, leukocyte count nadirs were <1,000/μL and platelet count nadirs were /100,000/μL in 38% and 15%, respectively, of the 39 patients for whom such data were available. Objective tumor regression occurred in ≈16% (95% confidence interval, 7%-30%) of the 44 patients (six, partial responses; one, complete response). For the 44 patients, median time to disease progression was 2.3 months; median time to death was 9.4 months. While this regimen was effective in three of 20 patients who had been previously treated with a doxorubicin-based regimen, only one of the 12 patients whose tumors had been primarily refractory to the doxorubicin-based regimen experienced objective tumor regression on our ifosfamide-based regimen. [J Natl Cancer Inst 81:863-866, 1989]

Original languageEnglish (US)
Pages (from-to)863-866
Number of pages4
JournalJournal of the National Cancer Institute
Issue number11
StatePublished - Jun 7 1989

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas'. Together they form a unique fingerprint.

Cite this